



## Peregrine Pharmaceuticals' Quarterly Conference Call Rescheduled for Tuesday, July 30

TUSTIN, Calif., Jul 24, 2002 (BW HealthWire) -- Peregrine Pharmaceuticals (Nasdaq:PPHM) has rescheduled its quarterly conference call for Tuesday, July 30, 2002 at 11:00 a.m. Eastern time. In order to participate, please phone (800) 822-4794 and reference confirmation code 749395 at least five minutes before the call is scheduled to begin. An audio replay will be available for two weeks at (888) 203-1112 (code 749395) and a transcript will be available on Peregrine's Web site, [www.peregrineinc.com](http://www.peregrineinc.com).

About Peregrine Pharmaceuticals, Inc.

Peregrine Pharmaceuticals is a biopharmaceutical company focused on the development, commercialization, and licensing of unique technologies for the treatment of cancer, primarily based on its three "collateral targeting technologies." Peregrine's Tumor Necrosis Therapy (TNT), Vasopermeation Enhancement Agents (VEA), and Vascular Targeting Agents (VTA) target cell structures and cell types that are common among solid tumor cancers, giving them broad applicability across various tumor types. The company's lead TNT anti-cancer drug, Cotara™, is currently in a multicenter Phase II clinical trial for brain cancer and Phase I trials for colorectal, pancreas, liver, soft tissue sarcoma and biliary cancers. Final preparations are being made to start a multi-center, multi-national Phase III trial for brain cancer. Peregrine's Oncolym®; for the treatment of non-Hodgkin's B-cell lymphoma, is currently in a multi-center Phase I/II study. Copies of Peregrine press releases, SEC filings, current price quotes and other valuable information for investors may be found on the Web site [www.peregrineinc.com](http://www.peregrineinc.com).

**Safe Harbor Statement:** This release may contain certain forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ from the company's expectations as a result of risk factors discussed in Peregrine's reports on file with the U.S. Securities and Exchange Commission, including, but not limited to, the company's report on Form 10-K for the year ended April 30, 2001 and on Form 10-Q for the quarter ended January 31, 2002.

CONTACT: Atkins + Associates  
Pam Lord (media), 858/860-0266 ext. 103  
[plord@irpr.com](mailto:plord@irpr.com)  
or  
Hawk Associates Inc.  
Frank Hawkins (investors), 800/987-8256  
<http://www.hawkassociates.com>

URL: <http://www.businesswire.com>  
Today's News On The Net - Business Wire's full file on the Internet  
with Hyperlinks to your home page.

Copyright &copy; 2002 Business Wire. All rights reserved.